Skip to main content
SCANCELL HOLDINGS PLC logo

SCANCELL HOLDINGS PLC — Investor Relations & Filings

Ticker · SCLP ISIN · GB00B63D3314 LEI · 2138008RXEG856SNP666 IL Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2024-07-02 Capital/Financing Update
Country GB United Kingdom
Listing IL SCLP

About SCANCELL HOLDINGS PLC

https://www.scancell.co.uk/

Scancell Holdings PLC is a clinical-stage company developing novel active immunotherapies for the treatment of cancer. Its approach focuses on enhancing long-lasting, tumor-specific immunity to address significant unmet needs in oncology, particularly for hard-to-treat cancers. The company leverages its proprietary technology platforms, Immunobody®, Moditope®, and AvidiMab™, to create targeted, off-the-shelf therapies. The Immunobody® platform generates DNA-based immunotherapies, with its lead candidate, iSCIB1+, targeting advanced melanoma. The Moditope® platform develops peptide-based therapies, with a lead product showing encouraging Phase 2 data in a broad range of solid tumors. Scancell aims to deliver treatments that are safe, effective, easily administered, and accessible to patients.

Recent filings

Filing Released Lang Actions
Extension of Convertible Loan Notes
Capital/Financing Update Classification · 99% confidence The document begins with an 'RNS Number' header and explicitly states it contains 'INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF EU REGULATION NO. 596/2014' (UK MAR). The content details an amendment to Convertible Loan Notes (CLN) redemption dates and interest terms, which is a significant corporate finance event. The document concludes with contact information and a standard disclaimer referencing RNS, the news service of the London Stock Exchange, and the Financial Conduct Authority (FCA). This structure is characteristic of a regulatory news service announcement. Since the announcement is about a change in financing terms (extension of loan notes and cash redemption), it strongly relates to 'Capital/Financing Update' (CAP). However, the primary function of this specific document format, identified by the RNS header and the nature of the disclosure (a material event announcement to the market), places it best under the general regulatory announcement category, RNS, which serves as the primary channel for such disclosures on the LSE.
2024-07-02 English
Block Listing Return and Total Voting Rights
Share Issue/Capital Change Classification · 99% confidence The document is a formal announcement released via RNS (RNS Number : 4774U) from Scancell Holdings Plc. The content primarily concerns two administrative/regulatory updates: 1) A Block Listing Return detailing the allotment of new ordinary shares and the resulting total voting rights, which is a mandatory disclosure under AIM Rules for Companies. 2) An announcement regarding the name change of its Nominated Adviser and Joint Broker. This type of short, formal notification covering administrative changes, share issuance updates (not a full capital raise), and regulatory compliance disclosures, which doesn't fit neatly into specific financial reports (10-K, IR, ER) or shareholder meeting materials (AGM-R, DEF 14A), is best classified as a general Regulatory Filing (RNS). Although it contains elements related to share changes (SHA/POS), the primary function here is the mandatory notification/return filing itself.
2024-07-01 English
Change of Nominated Advisor
Board/Management Information Classification · 99% confidence The document begins with 'RNS Number : 3032T' and contains standard boilerplate language referencing 'RNS, the news service of the London Stock Exchange' and compliance with MAR regulations. The core content is a brief announcement regarding a 'Change of Nominated Advisor' for Scancell Holdings Plc. This type of announcement, which is a specific corporate action update distributed via the Regulatory News Service (RNS), does not fit neatly into the defined categories like 10-K, ER, or DIV. Since it is a general regulatory announcement distributed through the official news service that doesn't match a more specific category, the appropriate fallback classification is Regulatory Filings (RNS). The document length is short (3641 chars), but it is reporting an event, not announcing the publication of a separate, larger report, so RPA is less appropriate than RNS for this specific type of regulatory update.
2024-06-21 English
Agreement with major biotech
M&A Activity Classification · 99% confidence The document is identified by the header 'RNS Number : 1151S' and contains standard boilerplate language referencing 'RNS, the news service of the London Stock Exchange' and compliance with MAR regulations. The content announces a significant business development: Scancell signing an agreement with a major biotechnology company to evaluate an antibody from its Glymab® portfolio, including an exclusivity payment. This type of announcement, which is a material, non-public event disclosure disseminated via the official regulatory news service (RNS), fits best under the general 'Regulatory Filings' category, as it is not a specific financial report (10-K, IR, ER) or a specific corporate action like a dividend or director dealing. Given the context of RNS dissemination, RNS is the most appropriate classification.
2024-06-12 English
Scancell to attend upcoming conferences
Regulatory Filings Classification · 99% confidence The document is identified by the RNS Number (5440Q) and contains a standard header indicating it is a regulatory announcement from the London Stock Exchange's news service (RNS). The content announces the company's attendance and presentation schedule at upcoming industry conferences ([BIO International Convention] and [Antibody Engineering & Therapeutics Europe]). This type of announcement, which informs the market about management/employee participation in external industry events rather than releasing core financial results, management changes, or shareholder votes, fits best under the general 'Regulatory Filings' category, as it is a routine disclosure made via the RNS system that doesn't map to a more specific category like ER, MANG, or DIV. Given the source (RNS) and the nature of the update (conference attendance), RNS is the most appropriate classification.
2024-05-31 English
Update on ModiFY trial
Regulatory Filings Classification · 100% confidence The document begins with an RNS Number (3616Q) and is dated May 30, 2024. The content is a press release from Scancell Holdings Plc announcing that it has received approval from the MHRA to expand its ModiFY clinical trial for its Modi-1 cancer vaccine. This type of announcement, detailing operational or clinical updates, is typically disseminated via regulatory news services. Since it is a specific, non-financial, non-shareholder meeting related announcement that doesn't fit other specific categories (like ER, 10-K, or DIV), and it is clearly distributed through the RNS system (as indicated by the header and footer), the most appropriate classification is Regulatory Filings (RNS). The document length is substantial (6746 chars), but its nature is that of a news announcement, not a full report like an IR or 10-K.
2024-05-30 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.